Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid inhibits platelet activation and thrombosis via inhibition of thromboxane A2 signaling and phosphodiesterase

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 10, 2013, Pages 1855-1866

  Zhang, S H ^a   Zhang, Y ^a   Shen, J ^b   Zhang, S ^a   Chen, L ^a   Gu, J ^a   Mruk, J S ^c   Cheng, G ^d   Zhu, L ^b   Kunapuli, S P ^e   Ding, Z ^a  

^a FUDAN UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiplatelet agents; Antitumor agents; DMXAA; Phosphodiesterase inhibitors; TXA2

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; MITOFLAXONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHODIESTERASE; RISTOCETIN; THROMBOXANE A2; THROMBOXANE SYNTHASE; VADIMEZAN;

ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTERIOLE; ARTERY THROMBOSIS; ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBOSIS; VASCULAR TUMOR;

ANTIPLATELET AGENTS; ANTITUMOR AGENTS; DMXAA; PHOSPHODIESTERASE INHIBITORS; TXA2;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; THROMBOSIS; THROMBOXANE A2; THROMBOXANE-A SYNTHASE; XANTHONES;

EID: 84885352873     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12362     Document Type: Article

References (31)

1. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011; 107: 1796-801.
2. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, Maida R, Collins M, Kreps E, Moses JW. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 99: 2364-6.
3. Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, Minami Y, Wang L, Kim EJ, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009; 119: 3207-14.
4. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fuca G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125: 2015-26.
5. Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 2965-71.
6. Pili R, Rosenthal MA, Mainwaring PN, van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong S, Clingan P. Phase II study on the addition of ASA404 (vadimezan; 5, 6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 2010; 16: 2906-14.
7. Fruh M, Cathomas R, Siano M, Tscherry G, Zippelius A, Mamot C, Erdmann A, Krasniqi F, Rauch D, Simcock M, Kuttel E, Fustier P, Pless M. Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). Clin Lung Cancer 2013; 14: 34-9.
8. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003; 4: 141-8.
9. Ching LM, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, Baguley BC. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 1999; 59: 3304-7.
10. Rubin J, Ames MM, Schutt AJ, Nichols WL, Bowie EJ, Kovach JS. Flavone-8-acetic acid inhibits ristocetin-induced platelet agglutination and prolongs bleeding time. Lancet 1987; 2: 1081-2.
11. Mruk JS, Webster MW, Heras M, Reid JM, Grill DE, Chesebro JH. Flavone-8-acetic acid (Flavonoid) profoundly reduces platelet-dependent thrombosis and vasoconstriction after deep arterial injury In vivo. Circulation 2000; 101: 324-8.
12. Pan C, Wei X, Ye J, Liu G, Zhang S, Zhang Y, Du H, Ding Z. BF066, a novel dual target antiplatelet agent without significant bleeding. PLoS ONE 2012; 7: e40451.
13. Zhang S, Hu L, Du H, Guo Y, Zhang Y, Niu H, Jin J, Zhang J, Liu J, Zhang X, Kunapuli SP, Ding Z. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism. Thromb Haemost 2010; 104: 845-57.
14. Jin YR, Cho MR, Ryu CK, Chung JH, Yuk DY, Hong JT, Lee KS, Lee JJ, Lee MY, Lim Y, Yun YP. Antiplatelet activity of J78 (2-Chloro-3-[2′-bromo, 4′-fluoro-phenyl]-amino-8-hydroxy-1, 4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization. J Pharmacol Exp Ther 2005; 312: 214-9.
15. Hu L, Fan Z, Du H, Ni R, Zhang S, Yin K, Ye J, Zhang Y, Wei X, Zhang X, Gross PL, Kunapuli SP, Ding Z. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y(1)(2) receptor and phosphodiesterase. Thromb Haemost 2011; 106: 1203-14.
16. Zhu L, Stalker TJ, Fong KP, Jiang H, Tran A, Crichton I, Lee EK, Neeves KB, Maloney SF, Kikutani H, Kumanogoh A, Pure E, Diamond SL, Brass LF. Disruption of SEMA4D ameliorates platelet hypersensitivity in dyslipidemia and confers protection against the development of atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 1039-45.
17. Atkinson BT, Jasuja R, Chen VM, Nandivada P, Furie B, Furie BC. Laser-induced endothelial cell activation supports fibrin formation. Blood 2010; 116: 4675-83.
18. Rustin GJ, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G. 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003; 88: 1160-7.
19. Needleman P, Raz A, Ferrendelli JA, Minkes M. Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets. Proc Natl Acad Sci USA 1977; 74: 1716-20.
20. Naik MU, Stalker TJ, Brass LF, Naik UP. JAM-A protects from thrombosis by suppressing integrin alphaIIbbeta3-dependent outside-in signaling in platelets. Blood 2012; 119: 3352-60.
21. Gambaryan S, Geiger J, Schwarz UR, Butt E, Begonja A, Obergfell A, Walter U. Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase. Blood 2004; 103: 2593-600.
22. Adam F, Kauskot A, Rosa JP, Bryckaert M. Mitogen-activated protein kinases in hemostasis and thrombosis. J Thromb Haemost 2008; 6: 2007-16.
23. Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010; 30: 2341-9.
24. Xiang B, Zhang G, Liu J, Morris AJ, Smyth SS, Gartner TK, Li Z. A G(i) -independent mechanism mediating Akt phosphorylation in platelets. J Thromb Haemost 2010; 8: 2032-41.
25. O'Brien KA, Stojanovic-Terpo A, Hay N, Du X. An important role for Akt3 in platelet activation and thrombosis. Blood 2011; 118: 4215-23.
26. Jameson MB, Sharp DM, Sissingh JI, Hogg CR, Thompson PI, McKeage MJ, Jeffery M, Waller S, Acton G, Green C, Baguley BC. Transient retinal effects of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials. Invest Ophthalmol Vis Sci 2009; 50: 2553-9.
27. Guerrero JA, Lozano ML, Castillo J, Benavente-Garcia O, Vicente V, Rivera J. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thromb Haemost 2005; 3: 369-76.
28. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007; 100: 1673-85.
29. Woulfe DS, Platelet G. protein-coupled receptors in hemostasis and thrombosis. J Thromb Haemost 2005; 3: 2193-200.
30. Kestell P, Paxton JW, Rewcastle GW, Dunlop I, Baguley BC. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5, 6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. Cancer Chemother Pharmacol 1999; 43: 323-30.
31. McKeage MJ, von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008; 99: 2006-12.